Visual and refractive outcomes of low-add refractive toric multifocal intraocular lens
Session Details
Session Title: Presented Poster Session: Multifocal IOLs
Venue: Poster Village: Pod 1
First Author: : K.Kim SOUTH KOREA
Co Author(s): :
Abstract Details
Purpose:
Evaluate clinical outcomes after implantation of new low-add refractive multifocal intraocular lens(IOL) with toricity.
Setting:
Retrospective study
Central Seoul Eye Center, Seoul, Korea
Methods:
Fifty eyes of 38 patients were enrolled in this study. New refractive toric multifocal IOL (Lentis® Comfort Toric) with +1.5 diopters(D) near addition was implanted to all subjects. After 6 months, manifest refraction, uncorrected distant visual acuity(UDVA), uncorrected intermediate visual acuity(UIVA) and uncorrected near visual acuity(UNVA) were evaluated. Contrast sensitivity was measured. Subjects completed a questionnaire on outcomes satisfaction, visual symptoms, and spectacles use 6 months following cataract surgery.
Results:
Uncorrected distant visual acuity changed from 0.35(pre-operative) to 0.98 1 months following surgery and remained unchanged after 6months. UIVA and UNVA were 0.85 and 0.6 at 6months. Astigmatism was reduced from 1.63D to 0.18D Patients who answered good or excellent at distant, intermediate, near were 96%, 92%, 62.5%. Although subjects who need spectacles were 2%, 4% at distant and intermediate, 48% answered they need glasses to read book. Twelve percent of subjects felt photic symptoms like glare or halo. Contrast sensitivity showed superior result compared to other multifocal IOLs.
Conclusions:
New refractive toric multifocal IOLs provided good distant and intermediate visual outcomes and corrected astigmatism effectively. Although the IOLs are designed for intermediate vision, over half subjects had enough vision to read book. It provided good visual and refractive quality even though all patients had astigmatism. This low-add(+1.50D) refractive toric multifocal IOLs will be useful to cataract surgery improving surgical outcomes and patient’s satisfaction.
Financial Disclosure:
NONE
